Re: No authors listed!!!!

[Guest guest]

Nelly

What people fail to realise and this is in general and on most

forums, is that using antibiotics adhoc creates problems.You'll fuel

inflammation with a course of macrolides if you have heart disease..

And you won't fix any of the associated organisms/problems.

The part of the medical establishment that's treated heart infections

for many years alway's states you never ever use bacteriostatic

antibiotics.. There's also the fact that when your using pill form

low levels of drugs you can create superinfections. This is actually

stated on the instruction sheet that comes with amoxacillin.

So to sum up, the strength, duration, and understanding the severity

of the person's problems are paramount to actually avoiding getting

someone worse.

I get so annoyed that people can quite simply view live blood and see

the mess it's in, yet can't use this same approach to target there

therapy...Imagine doing six months of useless therapies and

increasing your chance of death.

tony

>

>

> They only gave the patients 2 wks of abx!!! I just can't believe it

could've had an effect one way or the other two years down the line.

>

> Nelly

>

> http://tinyurl.com/ybryk8

>

>

> Prescrire Int. 2006 Dec;15(86):225.

> Clarithromycin in coronary heart disease: excess mortality in the

long term.

> [No authors listed]

> (1) Based on an attractive hypothesis implicating inflammation

caused by Chlamydia pneumoniae in cardiovascular disease, several

clinical trials have tested whether antibiotic therapy has a long-

term preventive effect. (2) One trial showed an increase in mortality

3 years after a 2-week course of clarithromycin in patients with

coronary heart disease (9.8% versus 7.8% in the placebo group). This

difference resulted mainly from higher cardiovascular mortality (5.1%

versus 3.5%). (3) A meta-analysis of all trials of antichlamydial

antibiotics (mainly macrolides) in the prevention of cardiac events

showed no difference between the groups in terms of cardiac morbidity

or mortality. However, trials with more than 2 years of follow-up

suggest that antimicrobial chemotherapy is associated with a

statistically significant increase in mortality. (4) In practice,

pending further information on the long-term effects of antimicrobial

chemotherapy in coronary heart disease patients, these disturbing

results suggest that the drugs are best avoided--especially

macrolides--except in situations where their use is clearly warranted.

>

> PMID: 17167932 [PubMed - in process]

>